Investing in reproductive health is not only a strategic financial move but also a moral imperative. By channeling our investment dollars into the critical areas described above, we can support innovative solutions, expand access to essential services, and uphold the fundamental rights of women across the nation.
The funding landscape for women's health companies is getting better, partially due to more women getting promoted at VC firms and social media, execs said during a recent panel.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Eli Lilly is among the new investors joining the Series B round of Arkuda Therapeutics, a biotech developing a drug to treat a rare, inherited form of dementia. If the biotech’s approach works, it could also have applications in other neurodegenerative conditions such as Alzheimer’s and Parkinson’s.
Biotech startup Congruence Therapeutics is developing novel drugs that treat disease by stabilizing misfolded proteins. Key to the company’s approach is a computational platform that discovers and designs these small molecule stabilizers.
Dewpoint is developing drugs targeting biomolecular condensates, tiny droplets in cells that contain proteins and nucleic acids. Dysfunction of these organelles can play a role in a wide range of diseases, including neurodegenerative disorders and cardiovascular disease.
Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives the biotech rights to a Janssen antibody designed to address the two types of influenza that cause seasonal flu.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
BenchSci’s technology uses artificial intelligence to make drug R&D faster and more efficient. Big pharmaceutical companies and clinical-stage biotechs are current users of the software, and BenchSci said it will use its new funding to expand the technology.
Eleusis is developing a formulation of the psychedelic compound psilocybin that overcomes limitations of pill versions of the drug. Depression is Eleusis’s lead disease target but the biotech notes that its research has shown the potential to bring psychedelic drugs beyond psychiatry.
Despite the targeted approach of some cancer treatments, tumors can find ways to escape, leading patients to relapse. ImmPACT Bio will apply its Series B financing toward the development of cell therapies designed to prevent tumor escape.
ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Digital health company Verana Health has raised $150 million. The company said it will use the new capital to expand its technology, which is used by physicians and pharmaceutical companies.
Three life science companies unveiled Series B rounds of funding Thursday, early Christmas gifts that top $219 million combined. Along with Verge Genomics, the other companies that raised new capital are Tasso and Brainomix.
Odyssey Therapeutics is the latest startup formed by serial biotech entrepreneur Gary Glick. Odyssey’s destination is oncology and immunology drugs that address novel disease targets, and the biotech now has $218 million in Series A financing to fuel the journey.
Nabla Bio emerged from the lab of famed Harvard scientist George Church last year, and its antibody discovery technology has already led to five partnerships with pharma and biotech companies. The startup just closed an $11 million seed financing that will support further development of its technology.
AviadoBio’s gene therapies are designed to achieve widespread distribution throughout the central nervous system. The company’s lead program on track to begin human testing as a treatment for frontotemporal dementia.